Abstract
The AlphaFold computer program predicted protein structures for the wholehuman genome, which has been considered as a remarkable breakthrough both inartificial intelligence (AI) application and structural biology. Despite thevarying confidence level, these predicted structures still could significantlycontribute to the structure-based drug design of novel targets, especially theones with no or limited structural information. In this work, we successfullyapplied AlphaFold in our end-to-end AI-powered drug discovery enginesconstituted of a biocomputational platform PandaOmics and a generativechemistry platform Chemistry42, to identify a first-in-class hit molecule of anovel target without an experimental structure starting from target selectiontowards hit identification in a cost- and time-efficient manner. PandaOmicsprovided the targets of interest and Chemistry42 generated the molecules basedon the AlphaFold predicted structure, and the selected molecules weresynthesized and tested in biological assays. Through this approach, weidentified a small molecule hit compound for CDK20 with a Kd value of 8.9 +/-1.6 uM (n = 4) within 30 days from target selection and after only synthesizing7 compounds. To the best of our knowledge, this is the first reported smallmolecule targeting CDK20 and more importantly, this work is the firstdemonstration of AlphaFold application in the hit identification process inearly drug discovery.